Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$4.73M$4.73M−4.3% vs Q2 2019 Net Income-$1.20M-$1.20MN/M vs Q2 2019 EPS Diluted-$0.92-$0.92N/M vs Q2 2019 Gross Profit$2,175,000−10.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$898,000N/M Free Cash Flowderived-$963,000N/M Margins · derivedGross margin46.0%−3.1 pt vs Q2 2019
Operating margin-27.2%+26.5 pt vs Q2 2019
Net margin-25.4%+31.6 pt vs Q2 2019
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end